Clinical Trial Update: Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing potential improvements in speech and hearing tests after 28 days of dosing with AUT00063 (QuicKfire) versus placebo in individuals with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hearing Impairment
• Hearing Loss

Drugs mentioned

• QuicKfire (AUT00063)

Snippet

Sponsor: Autifony Therapeutics Limited | Conditions: Hearing Loss, Hearing Impairment | Phase 2 | Status: COMPLETED